Artelo Biosciences
ARTL
4 hedge funds and large institutions have $25.6K invested in Artelo Biosciences in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0.01% less ownership
Funds ownership: 0.04% → 0.04% (-0.01%)
20% less funds holding
Funds holding: 5 → 4 (-1)
28% less capital invested
Capital invested by funds: $35.7K → $25.6K (-$10K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$3.11K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$824 |
| 3 |
Citigroup
New York
|
-$64 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $19.8K | -$3.11K | -136 | -12% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $5.8K | -$824 | -36 | -11% |
|
3
Bank of America
Charlotte,
North Carolina
| $29 | – | – | – |
|
4
Morgan Stanley
New York
| $22 | – | – | – |
|
|
RIL
5
Rothschild Investment LLC
Chicago,
Illinois
| $9 | – | – | – |
|
|
6
Citigroup
New York
| – | -$64 | -3 | Closed |
|
ARTL Hedge Fund Activity: Q3 2024 in Review
4 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q3 2024, worth a combined $25.6K — down 28% from $35.7K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ARTL and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest seller was Geode Capital Management, cutting an estimated $3.11K.
- 4 institutional investors held Artelo Biosciences (ARTL) as of Q3 2024, down from 5 in Q2 2024.
- Funds reported $25.6K of Artelo Biosciences stock for Q3 2024, down 28% quarter-over-quarter.
- 0 funds opened new Artelo Biosciences positions in Q3 2024 and 1 closed out, a net change of -1 holder.
- The largest Artelo Biosciences seller in Q3 2024 was Geode Capital Management, an estimated $3.11K sold.
Based on aggregated 13F filings for Q3 2024.